20. Deferred tax
|
31 December |
|
(thousands of €) |
2018 |
2017 |
Recognized deferred tax assets and liabilities |
|
|
Assets |
2,514 |
1,978 |
Liabilities |
|
|
|
|
|
Deferred tax assets unrecognized |
223,377 |
164,079 |
|
|
|
Deferred taxes in the consolidated income statement |
535 |
20 |
Tax benefit arising from previously unrecognized tax assets used to reduce deferred tax expense (+) |
1,973 |
414 |
Deferred tax expenses relating to change in tax rates |
|
(181) |
Deferred tax expenses relating to use of previously recognized deferred tax assets |
(1,438) |
(213) |
The investment deduction of €1 million (2017: €1 million) could give rise to deferred tax assets. There is no limit in time for the investment deduction. The amount of notional interest deduction that has been accumulated in the past (2017: €2.6 million) could not be carried forward to 2018, the notional interest deduction of the year itself can also not be carried forward.
The consolidated unused tax losses carried forward at 31 December 2018 amounted to €688.7 million (2017: €567 million), €5.7 million were related to unrecognized tax losses with expiry date between 2019 and 2030.
The available statutory tax losses carried forward that can be offset against future statutory taxable profits amounted to €374.2 million on 31 December 2018. These statutory tax losses can be compensated with future statutory profits for an indefinite period except for an amount of €10.8 million in Switzerland, Croatia and the United States with expiry date between 2019 and 2030. On 31 December 2018, the available tax losses carried forward in Galapagos NV (Belgium) amounted to €305.6 million. In addition to the latter, Galapagos NV (Belgium) also benefits from the new Belgian innovation income deduction regime which led to report, on 31 December 2018, a supplementary carried forward tax deduction amounting to €195.4 million that can also be offset against future statutory taxable results. It should be noted however that the Belgian corporate income tax reform introduced as of assessment year 2019 a de facto minimum taxable base, whereby the existing tax attributes have to be allocated into 2 so-called “baskets”: a first basket which contains the tax deductions that can be applied without any restrictions and a second basket which contains the tax deductions that are subject to restrictions. We refer to note 3 for more information.
We have a history of losses. Excluding the impact of possible upfront or milestone payments to be received from collaborations, we forecast to continue incurring taxable losses in the foreseeable future as we continue to invest in clinical and preclinical development programs and discovery platforms. Consequently, no deferred tax asset was set up as at 31 December 2018, except for one subsidiary operating on a cost plus basis and for our fee-for- service business, for which deferred tax assets were recognized for €2.5 million (2017: €2.0 million).